Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 1-Year High – Here’s Why

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares reached a new 52-week high during trading on Thursday . The company traded as high as $45.50 and last traded at $44.50, with a volume of 52320 shares. The stock had previously closed at $44.98.

Analyst Ratings Changes

Several research analysts have recently issued reports on KNSA shares. The Goldman Sachs Group lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Finally, Citigroup increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and an average target price of $52.33.

Kiniksa Pharmaceuticals International Stock Up 1.5%

The firm’s 50 day moving average is $42.21 and its 200-day moving average is $38.85. The firm has a market cap of $3.44 billion, a PE ratio of 100.82 and a beta of 0.06.

Insider Activity

In other news, Director Barry D. Quart sold 2,690 shares of the company’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $45.00, for a total transaction of $121,050.00. Following the completion of the transaction, the director owned 12,546 shares of the company’s stock, valued at $564,570. This represents a 17.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark Ragosa sold 17,845 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the transaction, the chief financial officer owned 12,086 shares in the company, valued at approximately $523,082.08. The trade was a 59.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 136,293 shares of company stock valued at $5,759,230 over the last quarter. Company insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently bought and sold shares of the stock. Amundi purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after acquiring an additional 1,002 shares during the last quarter. Millennium Management LLC grew its position in Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after acquiring an additional 67,452 shares during the period. Nordea Investment Management AB increased its stake in Kiniksa Pharmaceuticals International by 1.6% during the second quarter. Nordea Investment Management AB now owns 130,160 shares of the company’s stock worth $3,582,000 after acquiring an additional 2,110 shares during the last quarter. Finally, Cannon Global Investment Management LLC acquired a new stake in Kiniksa Pharmaceuticals International during the second quarter worth about $479,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.